Lifodrox

Moxifloxacin Hydrochloride, the active ingredient in Lifodrox, is a fluoroquinolone antibiotic presented as an ophthalmic solution for ocular use. It is formulated for topical administration to the eye and treats bacterial conjunctivitis, bacterial keratitis and other ocular bacterial infections in patients requiring prescription therapy.

GNH USA supplies Lifodrox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance and reliable logistics for global distribution. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and clinical use across multiple regions.

Lifodrox (moxifloxacin hydrochloride) is used to treat bacterial infections of the eye, targeting the ocular surface and cornea. - Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness, discharge and irritation. - Bacterial keratitis: eradicates causative organisms, promoting corneal healing and preserving visual acuity. - Other ocular bacterial infections: eliminates pathogens in conditions such as blepharitis or postoperative eye infections, supporting recovery.

Adverse ocular reactions may occur with Lifodrox use. Common Side Effects: - Stinging or burning sensation upon instillation. - Temporary blurred vision. - Redness of the conjunctiva. - Tearing or increased lacrimation. - Foreign body sensation. - Mild eyelid edema. Serious or Rare Side Effects: - Allergic contact dermatitis of the eyelid or periocular skin. - Severe eye pain or photophobia. - Corneal ulceration or perforation. - Vision loss or sudden decrease in visual acuity. - Persistent swelling of the conjunctiva. - Systemic hypersensitivity reactions (e.g., rash, fever).

Before prescribing Lifodrox, clinicians should consider the following precautions. - Hypersensitivity: verify patient has no known allergy to fluoroquinolones or any component of the formulation. - Indication: use only for confirmed or strongly suspected bacterial eye infections. - Contact lenses: advise patients to remove lenses during treatment and avoid reinsertion until therapy is completed. - Monitoring: observe for worsening signs or lack of improvement within 48–72 hours. - Ocular surface disease: avoid in patients with severe corneal epithelial defects or uncontrolled dry eye. - Store at room temperature: keep the bottle in its original packaging, protect from light and moisture.

Lifodrox may interact with other ophthalmic or systemic agents; consider the following. Major Interactions (Avoid): - Concurrent use of other ophthalmic antibiotics: may reduce efficacy or increase resistance risk. - Systemic fluoroquinolones: combined exposure can heighten risk of tendon or cartilage toxicity, though ocular exposure is low. Moderate Interactions (Monitor Closely): - Topical corticosteroids: may mask infection signs and delay healing. - Non‑steroidal anti‑inflammatory eye drops: could increase irritation. - Anticholinergic eye drops: may affect tear production and drug distribution. - Systemic medications that prolong QT interval: monitor cardiac status if high systemic exposure is anticipated.